In The News: Department of Brain Health
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.
NSUmethanide, an already approved drug for the treatment of swelling associated with conditions such as heart failure, improved cognitive test performance and reduced the accumulation of amyloid plaques in mice with conditions like Alzheimer’s disease.
Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
A generic drug used widely to treat swelling associated with hypertension and heart failure showed hints in early research that it may also prevent the devastating brain damage of Alzheimer’s disease, a surprising twist that suggests scientists have a lot more to learn about the root cause of the neurodegenerative condition.
UNLV is leading the way towards an eventual cure for Alzheimer’s with groundbreaking research.
Researchers at UNLV say they’ve strengthened the link between Type II diabetes and Alzheimer’s disease, which saps brain function and has no cure.
A team of neuroscientists from UNLV has confirmed the link between type 2 diabetes and Alzheimer's disease (AD) in a recent study published in the journal Communications Biology.
Type 2 diabetes may increase the risk of Alzheimer's disease by altering brain function, new animal research suggests.
tudy shows chronic hyperglycemia impairs working memory performance and alters fundamental aspects of working memory brain networks. The findings strengthen the link between type 2 diabetes and Alzheimer’s disease.
Type 2 diabetes may up the risk for Alzheimer's disease by altering brain function, new animal research suggests.
Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.